Skip to content
coobi
Back to the glossary

Relapse prevention medication for alcohol: evidence and limits

also: anti-craving medication · acamprosate · naltrexone

Relapse prevention combines therapy, aftercare and, in alcohol use disorder, often a medicine such as acamprosate or naltrexone. Their effect is documented but moderate, and they do not replace therapeutic work.

These are prescription medicines that reduce craving or blunt a substance's rewarding effect. This entry covers the medicines licensed for alcohol use disorder; opioid dependence has its own, separate treatments. They do not replace treatment, they support it.

What relapse prevention covers

The term covers everything that lowers the chance of relapse after withdrawal and rehabilitation. That includes psychotherapy, aftercare, peer groups, a written emergency plan and, where a doctor sees fit, a medicine.

In German-speaking countries these medicines are also called anti-craving substances. They act on craving or on the rewarding effect of alcohol and are used as part of an overall treatment plan.

Which medicines are licensed for alcohol

Acamprosate and naltrexone are the two most commonly used. Acamprosate acts on the balance between excitatory and inhibitory signalling and is directed at craving that arises from inner tension. Naltrexone blocks opioid receptors and reduces the reinforcing effect of alcohol.

Nalmefen is licensed for reducing consumption in particular circumstances. Opioid dependence has its own substitution treatments, which this page does not cover.

How large is the effect?

The German S3 guideline rates the evidence for acamprosate and naltrexone highly and recommends their use as part of an overall treatment plan.

A Cochrane review of acamprosate pooled 24 randomised trials with 6,915 participants. Compared with placebo, it cut the risk of any drinking to 86 percent of the placebo risk (RR 0.86, 95% CI 0.81 to 0.91), a number needed to treat of about 9 (NNT 9.09). The authors conclude “Acamprosate appears to be an effective and safe treatment strategy for supporting continuous abstinence after detoxification” (Rösner and colleagues, 2010).

A second Cochrane review of naltrexone pooled 50 trials with 7,793 patients. It reduced the risk of heavy drinking to 83 percent of the placebo risk (RR 0.83, 95% CI 0.76 to 0.90). Its effect on return to any drinking did not reach statistical significance (RR 0.96, 95% CI 0.92 to 1.00). Naltrexone therefore helps mainly to keep a slip from turning into heavy drinking (Rösner and colleagues, 2010).

Both author groups describe the effects as moderate and ask readers to weigh them against the relapsing nature of the disease and the few treatment options available.

Side effects and limits

With acamprosate, diarrhoea was the only side effect reported more often than with placebo (risk difference 0.11). With naltrexone, gastrointestinal problems such as nausea (risk difference 0.10) and daytime sleepiness (risk difference 0.09) were more frequent.

These medicines do not make the difference alone. They make the therapeutic work easier without replacing it. Whether such treatment is appropriate, which preparation fits and what argues against it is always a decision for the treating doctor.

Relapse prevention without a medicine

A large part of prevention consists of things a person can prepare. Someone who knows their triggers and has a written plan with names and phone numbers does not have to decide from scratch at the moment of greatest tension.

Building blocks that medicines add to

  • Aftercare and a peer group after rehabilitation
  • A written emergency plan with concrete contacts
  • Knowing your own triggers and early warning signs
  • Regular medical or therapy appointments, including in good phases
  • Relatives who know what to do when it matters

Common questions

What is relapse prevention in alcohol use disorder?

It covers all measures that lower the risk of relapse after withdrawal and rehabilitation, including therapy, aftercare, peer support, an emergency plan and often a medicine such as acamprosate or naltrexone.

Which medicines are used to prevent relapse in alcohol use disorder?

Acamprosate and naltrexone are the most commonly used. Nalmefen is licensed for reducing consumption in particular circumstances. The choice belongs to the treating doctor.

How well do acamprosate and naltrexone work?

According to Cochrane reviews, acamprosate cuts the risk of any drinking to 86 percent of the placebo risk (24 trials, 6,915 participants, NNT about 9). Naltrexone cuts the risk of heavy drinking to 83 percent (50 trials, 7,793 participants). The effects are moderate.

Does a medicine replace therapy?

No. The German S3 guideline recommends acamprosate and naltrexone as part of an overall treatment plan. They make therapeutic work easier without replacing it.

Please note

This glossary is for information and does not replace medical or therapeutic advice, diagnosis or treatment. If you think you or someone close to you may be affected, speak to a doctor or an addiction counselling service near you.

In an emergency

If there is immediate danger, call 112 anywhere in the EU, or 999 in the UK. In Germany, Telefonseelsorge is free around the clock on 0800 111 0 111 and 0800 111 0 222, and the addiction and drug helpline is on 01806 313 031. In the UK and Ireland, Samaritans is free around the clock on 116 123.

coobi care

Support between appointments

The move from a clinic back into everyday life is a particularly demanding phase of treatment. coobi care accompanies people through aftercare in daily life and gives the treating team a picture of how the time between sessions is going. It does not replace treatment.